Buy Adripeg 20 Doxorubicin Hydrochloride Liposomal (Pegylated Liposomal

Adripeg 20 contains doxorubicin hydrochloride liposomal (pegylated liposomal) 20mg/10ml in vials for injectable use. This formulation is designed for targeted delivery in chemotherapy regimens. Store between 2-8°C and protect from light. Consult a healthcare provider for suitability.

Strength

20mg/10ml

Pack Size

Storage

2-8°

Manufacturer / TM Owner

SPAL Pvt Ltd

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Uses / Indications

Adripeg 20 is used in chemotherapy for certain types of cancer, including ovarian cancer and Kaposi’s sarcoma. It belongs to a class of medications called anthracyclines, which work by slowing or stopping cancer cell growth. Patients often ask, 'what is Adripeg 20 used for' in relation to treatment plans. It may also be prescribed for other conditions as determined by a physician.

Side Effects

Adripeg 20 works by interfering with the growth of cancer cells, though individual responses vary. Some patients may experience fatigue or changes in blood counts during treatment. Hair loss and nausea are commonly reported effects. These effects are not guarantees of treatment outcome and should be discussed with a healthcare provider.

Precautions & Warnings

Adripeg 20 should be handled with care and administered by trained professionals. Avoid exposure to extreme temperatures and keep vials refrigerated between 2-8°C. Protect from light until ready for use. Do not use if the solution is discolored or contains particles. Always follow healthcare provider instructions for safe handling.

Avoid Interactions

Adripeg 20 may interact with other medications, including certain chemotherapy drugs and CYP450 inhibitors. Alcohol and live vaccines should be avoided during treatment. Patients on other therapies should inform their healthcare provider to assess potential risks. Always disclose all medications and supplements being used.

References

Frequently Asked Questions

Adripeg 20 is used in chemotherapy for certain cancers like ovarian cancer and Kaposi’s sarcoma.

Adripeg 20 is given as an intravenous infusion by a healthcare professional.

Common effects may include fatigue, nausea, and changes in blood counts.

Adripeg 20 is available through licensed pharmacies with a valid prescription.

Store Adripeg 20 between 2-8°C and protect from light until use.

Published by GNH India Pharmaceuticals Limited

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.